Posts

From EU Innovation to GCC Execution. An Opinion by Dr. Anjo De Heus of 360disruption.com

Image
From EU Innovation to GCC Execution: Why Venture Building Wins When Pilots Fail Across Europe, thousands of #healthtech and #biotech innovations are rigorously evaluated, funded, and technically validated through programs like Horizon Europe and the European Innovation Council. Many pass some of the toughest technical scrutiny in the world. And yet — too many of them stall. Not because the technology doesn’t work. But because commercialization, market entry, and execution are treated as afterthoughts. This is where venture building — properly done — changes the equation. The Pilot Problem The global health innovation ecosystem is crowded with pilots. Pilot projects. Pilot deployments. Pilot funding rounds. Pilot memorandums of understanding. Pilots create activity. They create headlines. They create temporary optimism. But they rarely create scale. In the GCC, and particularly in the UAE, this is well understood. Governments and regulators are not looking for endless pilots. They are l...
Post a Comment
Read more

Real work doesn’t trend as well as the next big idea in a polished deck - By Dr. Anjo De Heus 360disruption.com

Image
A Friday morning thought. #Execution  isn’t sexy. #Proven  solutions are boring. Real work doesn’t trend as well as the next big idea in a polished deck. But execution is what’s actually needed. Across  #Africa , I see enormous  #energy  around  #opportunity  — new  #alliances , new  #councils , new  #narratives . AND alongside that, I see people quietly deploying solutions that already work: building  #clinics , running  #diagnostics ,  #training  teams, fixing  #systems , staying when it’s hard. The gap isn’t  #vision . It’s follow-through. We don’t lack  #innovation . We lack  #disciplined  deployment at scale. #Sustainable   #impact  rarely comes from what’s new. It comes from what’s tested, adaptable, and repeatable — implemented with patience and accountability. This isn’t anti-innovation. It’s pro-outcomes. Maybe it’s time we made execution a little more  #attractive ...
Post a Comment
Read more

From Distressed Assets to Sovereign Capability — Thought Leadership by Dr. Anjo De Heus

Image
Why Africa’s Biotech Future May Be Built, Not Invented** Over the past weeks, I’ve been looking closely at something that doesn’t get nearly enough attention in global health and development conversations:  distressed biotech and pharmaceutical assets . In the United States and Europe, there are dozens of biotech and pharma companies sitting in various states of distress — not because the science failed, but because capital cycles shifted, timelines stretched, or strategic priorities changed. Some are in restructuring. Some in bankruptcy. Others are quietly being carved up for parts. What’s striking is this:  many of these assets still work . They have IP. They have data. They have GMP-grade processes, equipment, or know-how. They are not dead. They are simply  orphaned . At the same time, Africa — a continent of more than 1.4 billion people — remains overwhelmingly dependent on imports for essential medicines, biologics, diagnostics, and APIs. Not because of a lack of ta...
Post a Comment
Read more